Methyliensinine lipidosome

Abstract

The preparation method of the neferine liposome comprises the following steps: mixing a membrane material solution with a neferine solution to obtain a mixed solution; removing the organic solvent in the mixed solution to obtain a lipoid film; a hydrated lipoid film is obtained; and obtaining the neensinine lipidosome. According to the application, the problem of low skin absorption efficiency of neferine can be effectively solved, neferine can be transferred into cells more effectively, and the technical effect of preventing and treating skin photoaging is enhanced. Meanwhile, the stability of the neensinine is improved, the irritation is reduced, and then the activity and application universality of the neensinine are improved.

Description

Technical Field

[0001] This invention relates to the fields of medicine and skincare, and particularly to a methylnepene liposome. Background Technology

[0002] Photoaging of the skin is damage caused by prolonged exposure to sunlight, resulting from the combined effects of natural aging and ultraviolet radiation. Accumulated ultraviolet radiation from sunlight can cause thinning of the epidermis, degeneration and breakage of collagen fibers in the dermis, and even chromosomal gene alterations. Clinical manifestations of photoaging include roughness, thickening, dryness, sagging, and atrophy of the exposed skin, thinning of the dermis, reduced elasticity, deepening and thickening of wrinkles, excessive pigmentation or telangiectasia in localized areas, and may even lead to a series of skin diseases such as actinic keratosis, solar lentigines, colloid milia, squamous cell carcinoma, malignant melanoma, and skin cancer.

[0003] Patent CN201610334063.X first proposed that methyl lotusine may have a preventive effect against photoaging. However, due to the low skin absorption efficiency of methyl lotusine, its application in skin care is limited. Summary of the Invention

[0004] To address the technical problems existing in the prior art, this invention proposes a method for preparing methyl lotusine liposomes, comprising: mixing a membrane material solution with a methyl lotusine solution to obtain a mixed solution; preferably, the membrane material solution includes: DSPC, cholesterol, DSPE-PEG2000, and DSPE-PEG2000-COOH; removing the organic solvent from the mixed solution to obtain a lipid membrane; hydrating the lipid membrane with a phosphate buffer solution; ultrasonically treating the hydrated lipid membrane to obtain a liposome suspension; and squeezing the suspension through a membrane with pores of a certain diameter to obtain methyl lotusine liposomes.

[0005] In the preparation method described above, the molar ratio of DSPC, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-COOH is 2:(0.5-1.5):(0.07-0.15):(0.015-0.028), preferably 2:1:0.11:0.021.

[0006] In the preparation method described above, the methyl lotusine solution is a solution obtained by dissolving methyl lotusine in an organic solvent; preferably, the organic solvent is selected from methanol, ethanol, and DMSO.

[0007] In the preparation method described above, the solvent in the membrane solution is an organic solvent; preferably, the organic solvent is selected from methanol, ethanol, and DMSO.

[0008] As described above, the method for removing organic solvents from the mixed solution to obtain a lipid film is as follows: the mixed solution is subjected to rotary vacuum distillation in a constant temperature water bath for a certain period of time; preferably, the temperature of the constant temperature water bath is 50-70℃; preferably, the temperature of the constant temperature water bath is 60℃.

[0009] A methylnephrine liposome prepared according to any of the methods described above, which is configured to improve the skin absorption efficiency of methylnephrine.

[0010] The methylnephrine liposomes described above have a particle size of 3-40 nm; preferably, the particle size is 5-25 nm; more preferably, the particle size is 5-20 nm; and more preferably, the particle size is about 8-15 nm.

[0011] A skin care or pharmaceutical composition for preventing and / or treating photoaging damage of the skin, comprising methyl lotusine liposomes prepared according to any of the preparation methods described above, or methyl lotusine liposomes as described in any of the above methods.

[0012] The skin care or pharmaceutical composition described above is in the form of cream, gel, dressing, spray, ointment, patch, mask, lotion, or liquid.

[0013] The application of a methylnecholine liposome in the preparation of skin care products or pharmaceuticals for the prevention and / or treatment of photoaging damage to the skin.

[0014] A method for improving the skin absorption efficiency of methylnephrine includes: modifying methylnephrine to obtain methylnephrine liposomes.

[0015] The method described above, wherein the method for obtaining methylcaesin liposomes by modifying methylcaesin comprises: mixing a membrane material solution with a methylcaesin solution to obtain a mixed solution; removing the organic solvent from the mixed solution to obtain a lipid film; obtaining a hydrated lipid film; and obtaining methylcaesin liposomes.

[0016] This application effectively solves the problem of low skin absorption efficiency of methylcaesin, enabling it to be more effectively translocated into cells and enhancing its technical effect in preventing and treating skin photoaging. Simultaneously, this application improves the stability and reduces the irritation of methylcaesin, thereby increasing its activity and applicability. Attached Figure Description

[0017] The preferred embodiments of the present invention will now be described in further detail with reference to the accompanying drawings, wherein:

[0018] Figure 1 This is a bar chart showing the particle size distribution of methylnepenone liposomes according to an embodiment of the present invention;

[0019] Figure 2This is the ultraviolet absorption spectrum of methylnephrine liposomes according to an embodiment of the present invention;

[0020] Figure 3 This describes the transdermal efficacy of methylnephrine liposomes and methylnephrine according to an embodiment of the present invention.

[0021] Figure 4A These are β-galactosidase staining images of cells after different treatments according to an embodiment of the present invention;

[0022] Figure 4B This is a statistical analysis of β-galactosidase staining results of cells after different treatments according to an embodiment of the present invention;

[0023] Figure 5A These are ROS fluorescence images of cells after different treatments according to an embodiment of the present invention;

[0024] Figure 5B The SOD enzyme activity of cells after different treatments according to an embodiment of the present invention; and

[0025] Figure 6 These are electron micrographs of mouse skin after different treatments according to an embodiment of the present invention. Detailed Implementation

[0026] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0027] In the following detailed description, reference can be made to the accompanying drawings, which form part of this application and illustrate specific embodiments of the present application. In the drawings, similar reference numerals describe substantially similar components in different figures. Specific embodiments of the present application are described in sufficient detail below to enable those skilled in the art to implement the technical solutions of the present application. It should be understood that other embodiments may also be utilized, or structural, logical, or electrical changes may be made to the embodiments of the present application.

[0028] The proper nouns mentioned in this article have the following meanings:

[0029] The term "liposome" as used in this article refers to a molecularly ordered structure formed by phospholipids through hydrophobic association with other amphoteric compounds such as cholesterol dispersed in an aqueous phase. It is a multilayered vesicle structure exhibiting characteristics of biological membranes, hence also known as an artificial biological membrane. Liposomes are amphoteric surfactants with a very broad encapsulation range, capable of encapsulating water-soluble, lipid-soluble, and amphoteric substances.

[0030] The "methylnepenone" and "Nef" mentioned in this article are usually extracted from the green embryo of mature seeds of lotus (Nelumbo nucifera), a plant in the Nymphaeaceae family. They are soluble in organic reagents, insoluble in water, and soluble in ethanol, DMSO, etc., except for methanol. They are effective plant-derived antioxidants. They scavenge O2. 2- Although its effect is less than that of SOD, its scavenging effect on ·OH- is stronger than that of mannitol, a typical hydroxyl radical scavenger, and its scavenging effect is more obvious, indicating that its main function is scavenging, while its influence on the generation process of oxygen free radicals is small. Its mechanism of action may be related to the presence of phenolic hydroxyl groups in the molecular structure of methyl lotusine, and the hydrogen on the phenolic hydroxyl group can easily combine with oxygen free radicals, thus exhibiting antioxidant efficacy.

[0031] Studies have shown that methylcaesin has a protective effect against electrolytic oxygen free radical damage in isolated rat hearts, significantly reducing the incidence of ventricular arrhythmias induced by electrolytic oxygen free radical damage in isolated rat hearts, and decreasing the release of lactate dehydrogenase and the production of MDA in cardiomyocytes. Methylcaesin can counteract the reduction in coronary blood flow, left ventricular pressure (LVP), and ±dp / dtmax caused by oxygen free radicals, and also has a protective effect against oxygen free radical-induced vascular endothelial cell damage, which may be related to its oxygen free radical scavenging effect.

[0032] The "methylcaesin liposomes" described herein are obtained by uniformly mixing a methylcaesin solution with a membrane material solution, followed by ultrasonication, extrusion, or other operations. The methylcaesin solution is a solution obtained by dissolving methylcaesin in any solvent; in some embodiments, the solvent can be organic solvents such as methanol, ethanol, or DMSO. In some embodiments, the membrane material is a reagent that has been treated to encapsulate methylcaesin, thereby obtaining methylcaesin liposomes.

[0033] According to one embodiment of this application, the particle size of the methyl lotusine liposomes is about 14nm-130nm, preferably about 15nm-120nm, more preferably about 18nm-128nm, and even more preferably, the particle size is concentrated at about 21.04nm. Meanwhile, the dispersion index (PDI) of the methyl lotusine liposomes is about 0.236, as obtained by ultraviolet detection of the absorption spectrum in the wavelength of 250-500nm.

[0034] This application relates to a method for preparing methyl lotusine liposomes, comprising: mixing a membrane material solution with a methyl lotusine solution to obtain a mixed solution; subjecting the mixed solution to rotary vacuum distillation in a constant temperature water bath for a certain time; preferably, the temperature of the constant temperature water bath is 50-70℃; preferably, the temperature of the constant temperature water bath is 60℃ to remove organic solvents from the mixed solution to obtain a lipid membrane; adding phosphate buffer to the lipid membrane to obtain a hydrated lipid membrane; ultrasonically treating the hydrated lipid membrane to obtain a liposome pre-suspension; and extruding the liposome pre-suspension through a membrane with a specific pore size to obtain methyl lotusine liposomes.

[0035] In some embodiments, the membrane solution includes DSPC, cholesterol, DSPE-PEG2000, and DSPE-PEG2000-COOH. In some embodiments, the molar ratio of DSPC, cholesterol, DSPE-PEG2000, and DSPE-PEG2000-COOH is 2:(0.5-1.5):(0.07-0.15):(0.015-0.028), preferably 2:1:0.11:0.021.

[0036] In some embodiments, the solvent in the membrane solution is an organic solvent; preferably, the organic solvent is selected from methanol, ethanol, and DMSO. While methanol is the organic solvent mentioned in this application, this application does not actually limit the organic solvent in any way.

[0037] In some embodiments, the methylcaesin solution is a solution obtained by dissolving methylcaesin in an organic solvent; preferably, the organic solvent is selected from methanol, ethanol, DMSO, etc. While methanol is the organic solvent mentioned in this application, this application does not actually limit the organic solvent in any way.

[0038] Therefore, this application relates to a methylcaesin liposome prepared according to the above method, which is configured to improve the skin absorption efficiency of methylcaesin. In some embodiments, the particle size of the methylcaesin liposome is 3-40 nm; preferably, the particle size is 5-25 nm; more preferably, the particle size is 5-20 nm; and more preferably, the particle size is about 8-15 nm.

[0039] This application relates to a skin care or pharmaceutical composition for preventing and / or treating photoaging damage of the skin, comprising methyl lotusine liposomes prepared according to the above-described method for preparing methyl lotusine liposomes.

[0040] In some embodiments, the skin care product or pharmaceutical composition is in the form of a cream, gel, dressing, spray, ointment, patch, mask, lotion, or liquid.

[0041] This application also relates to the use of a methylnephrine liposome in the preparation of skin care products or pharmaceuticals for the prevention and / or treatment of photoaging damage to the skin.

[0042] In some embodiments, methods for preventing and / or treating photoaging damage to the skin include applying methyl limonene liposomes to the surface of a target skin. The target skin is skin that may be exposed to light or skin that has already suffered photoaging damage.

[0043] This application relates to a method for improving the skin absorption efficiency of methylcaesin, comprising: modifying methylcaesin to obtain methylcaesin liposomes.

[0044] One method for obtaining methylcaesin liposomes by modifying methylcaesin includes: mixing a membrane material solution with a methylcaesin solution to obtain a mixed solution; removing the organic solvent from the mixed solution to obtain a lipid film; obtaining a hydrated lipid film; and obtaining methylcaesin liposomes.

[0045] Example 1: Preparation method of methylnepenone liposomes

[0046] The reagents involved in this embodiment, such as cholesterol, DSPC, DSPE-PEG2000-COOH, and DSPE-PEG2000, are all commercially available.

[0047] In this embodiment, the lipid solution contains DSPC with a molecular weight of 790.15, purchased from Shanghai Pengsheng Biotechnology Co., Ltd.; cholesterol with a molecular weight of 386.66, purchased from Shanxi Youchen Biotechnology Co., Ltd.; DSPE-PEG2000 with a molecular weight of 2808.74, purchased from Shanghai Pengsheng Biotechnology Co., Ltd.; and DSPE-PEG2000-COOH with a molecular weight of 2780.38, purchased from Shanghai Pengsheng Biotechnology Co., Ltd.

[0048] Weigh 0.19g of DSPC, 0.046g of cholesterol, 0.038g of DSPE-PEG2000, and 0.008g of DSPE-PEG2000-COOH into a membrane material; dissolve the membrane material in 40ml of chloroform to obtain a membrane material solution; wherein the molar ratio of DSPC, cholesterol, DSPE-PEG2000, and DSPE-PEG2000-COOH is 2:(0.5-1.5):(0.07-0.15):(0.015-0.028), preferably 2:1:0.11:0.021.

[0049] Weigh 200 mg of methylnephrine, place it in a 50 ml centrifuge tube, and dissolve it in 10 ml of methanol;

[0050] Add the membrane material solution to the methyl lotusine-methanol solution and stir until homogeneous;

[0051] The organic solvent was removed by rotary vacuum distillation in a 60℃ constant temperature water bath, forming a uniform lipid film on the bottle wall. The solution was then rotated for 30 minutes to remove the residual solvent.

[0052] The lipid membrane was hydrated with phosphate-buffered saline (PBS) at pH 7.5 and stirred for 1 hour.

[0053] The liposomes were sonicated (300W, 1.0MHz) for 20 minutes to form a preliminary suspension. The suspension was then squeezed through a 0.45μm membrane to form clear methylnephrine liposomes.

[0054] After the initial liposome suspension is extruded through membranes of different pore sizes, the liposome particle size becomes smaller and more uniform, and the liposomes appear clear and without obvious precipitation. In this embodiment, the liposomes are extruded through a 0.45 μm membrane. In fact, this application does not limit the material of the membrane used for extrusion, the pore size of the membrane, etc.

[0055] Figure 1 This is a bar chart showing the particle size distribution of methylnepenone liposomes according to an embodiment of the present invention; as shown. Figure 1 As shown, the particle size of the methyl lotusine liposomes is 3-40 nm; preferably, the particle size is 5-25 nm; more preferably, the particle size is 5-20 nm; and more preferably, the particle size is about 8-15 nm.

[0056] Figure 2 This is the ultraviolet absorption spectrum of methylnephrine liposomes according to an embodiment of the present invention; according to Figure 2 It is evident that the absorbance of methylnepenone liposomes (Nef-Lipo) is lower than that of Nef.

[0057] Example 2: Transdermal properties of methylnephrine liposomes

[0058] In this embodiment, the applicant compared the transdermal properties of methylnephrine liposomes (Nef-Lipo) and Nef. The specific experimental procedures are as follows:

[0059] 1. Select male SD rats weighing (180±20)g and sacrifice them by dislocation of the neck;

[0060] 2. Shave the chest and abdomen, avoiding the nipples, remove the full layer of skin, remove any remaining hair, and gently separate the epidermis from the subcutaneous tissue with a cotton swab and check the integrity of the skin;

[0061] 3. Place the entire piece of skin between the two chambers of the Franz diffusion chamber (dermis facing the receiving chamber), with the bottle opening smaller than the skin area, clamp the upper and lower chambers together and seal the gap;

[0062] 4. Add 2 ml of drug to the drug delivery pool; wherein the drug is a drug containing Nef-Lipo or Nef alone; further, the drug containing Nef-Lipo is 0.1% (w / v) Nef-Lipo obtained by mixing with 1.5% carbomer gel as solvent; the drug containing Nef is 0.1% (w / v) Nef obtained by mixing with 1.5% carbomer gel as solvent;

[0063] 5. Slowly add methanol from the sampling port of the receiving pool until all air bubbles are expelled, then seal the opening of the drug delivery pool and the sampling port;

[0064] 6. Heat at a constant temperature of 37℃, and take 1 mL of the receiving solution at 0h, 0.5h, 1h, 2h, 4h, 6h, 12h, and 24h respectively, and add an equal amount of methanol.

[0065] 7. Take a 0.22μm filter membrane and filter the sample in several batches;

[0066] 8. The obtained samples can be quantitatively analyzed by high performance liquid chromatography (HPLC) to compare transdermal performance.

[0067] Figure 3 This paper compares the transdermal performance of Nef-Lipo and Nef according to an embodiment of the present invention. As shown in the accompanying figures, Nef-Lipo exhibits better skin absorption than Nef one hour after administration, and the difference in transdermal efficacy between the two gradually increases over time. These results demonstrate that the Nef-Lipo drug delivery system constructed in this experiment significantly improves upon the technical bottlenecks of poor transdermal permeability and limited bioavailability of Nef through transdermal drug delivery.

[0068] Example 3 β-galactosidase staining

[0069] Age-related β-galactosidases are widely used as biomarkers for replicative aging. In this embodiment, methylcaesin encapsulated in liposomes was used for cell experiments. Specifically, liposomes without methylcaesin, methylcaesin alone, and methylcaesin liposomes were divided into light-protected and UVA-exposed groups, respectively, and then mixed with skin fibroblasts.

[0070] Group 1: Also known as NU-DM group, without added methylnephrine liposomes, protected from light;

[0071] Group 2: Also known as NU-Nef group, simple methylnephrine, protected from light;

[0072] Group 3: Also known as NU-Lipo group, methylnepenone liposomes, protected from light;

[0073] Group 4: Also known as the U-DM group, without the addition of methylnephrine liposomes, UVA light irradiation;

[0074] Group 5: Also known as the U-Nef group, consisting of simple methylnephrine, UVA light exposure; and

[0075] Group 6: Also known as U-Lipo group, methyl lotusine liposomes, UVA light irradiation.

[0076] DM refers to DMEM medium without any additional components; Nef refers to DMEM medium with added methylcaenine at a concentration of 0.8 mM; UVA irradiation of cells: approximately 10 J / cm². 2 / day, irradiated for 7 days.

[0077] After establishing the UVA irradiation model in vitro, the cells in each group were stained with β-galactosidase using a kit, and observed under a microscope 24 hours after staining. Experimental results were recorded by selecting microscopic fields of view with similar cell density.

[0078] Figures 4A-4B The results of β-galactosidase staining of cells after different treatments in this embodiment are shown. As shown in the figure, the number of stained cells in group 4 is significantly greater than that in group 1, verifying the effectiveness and feasibility of the above modeling method. In addition, the number of stained cells in groups 5 and 6 is reduced compared with group 4, and is close to the number of stained cells in groups 1-3, indicating that methyl lotusine may have a preventive and inhibitory effect on photoaging of primary fibroblasts.

[0079] Example 4 Antioxidant Detection

[0080] In this embodiment, methyllimonene encapsulated in liposomes was used for antioxidant assays. After treatment and modeling of groups 1-4, the ROS fluorescence intensity of primary fibroblasts in each group was measured. SOD enzyme activity was measured after protein extraction from fibroblasts in each group. The ROS fluorescence intensity was measured using fluorescent labeling methods known in the art, and the fibroblast protein extraction and SOD enzyme activity assays were performed using commercially available kits, which will not be elaborated upon here.

[0081] Group 1: Also known as NU-DM group, without added methylnephrine liposomes, protected from light;

[0082] Group 2: Also known as the U-DM group, without the addition of methylnephrine liposomes, UVA light irradiation;

[0083] Group 3: Also known as the U-Nef group, consisting of simple methylnephrine, UVA light exposure; and

[0084] Group 4: Also known as U-Lipo group, methyl lotusine liposomes, UVA light irradiation.

[0085] Among them, UVA light irradiation of cells: ultraviolet radiation approximately 10 J / cm 2 / day, irradiated for 7 days.

[0086] Figures 5A-5B These are ROS fluorescence intensity images and SOD enzyme activity results of cells after different treatments according to this embodiment. Figure 5A As shown, the fluorescence intensity of group 2 was significantly stronger than that of group 1, and also stronger than that of groups 3 and 4, proving that groups 3 and 4 can effectively inhibit the increase of ROS. Figure 5B As shown in the experiment, the oxidative stress level of group 2 was significantly higher than that of group 1 after ultraviolet irradiation modeling, while groups 3 and 4 had significant inhibitory effects on oxidative stress. Moreover, group 4 had a more lasting and stable effect than group 3, and had a good sustained-release effect.

[0087] Example 5 Animal Skin Test

[0088] In this embodiment, the inventors selected mice of the same age and grouped them according to groups 1-4 in Example 4. After hair removal, the corresponding reagents were applied to the skin, and the mice were further treated with light protection or ultraviolet light. The ultraviolet light irradiation dose was approximately 10 J / cm². 2 / day, irradiated for 60 days.

[0089] Figure 6 These are electron micrographs of mouse skin after different treatments according to this embodiment. For example... Figure 6 As shown, the skin in groups 2-4 showed significant photoaging damage compared to group 1, while the skin in groups 3 and 4 showed lower levels of photoaging. Among them, the skin in group 4 showed significantly lower levels of photoaging than that in group 3. This indicates that methyl lotusine liposomes have a better effect on preventing and treating skin photoaging than methyl lotusine alone.

[0090] This application utilizes the similarity between liposome components and cell membranes to encapsulate methylcaproic acid within liposomes. Methylcaproic acid is then transferred into cells via endocytosis or membrane fusion, effectively solving the problem of short transdermal retention time of methylcaproic acid. This results in a good sustained-release effect, significantly increasing the duration of action of methylcaproic acid and enabling more effective transfer into cells. Simultaneously, it improves the stability of methylcaproic acid and reduces irritation, thereby enhancing its activity and broadening its application.

[0091] The above embodiments are for illustrative purposes only and are not intended to limit the invention. Those skilled in the art can make various changes and modifications without departing from the scope of the invention. Therefore, all equivalent technical solutions should also fall within the scope of the invention.

Claims

1. A method for preparing methylnepenone liposomes, comprising: The membrane material solution is mixed with the methyl lotusine solution to obtain a mixed solution; preferably, the membrane material solution includes: DSPC, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-COOH; Remove the organic solvent from the mixed solution to obtain a lipid film; Lipid membranes are hydrated using phosphate buffer solution; The hydrated lipid membrane was subjected to ultrasonic treatment to obtain a liposome suspension; and The initial suspension is squeezed through a membrane with pores of a certain diameter to obtain methyl lotusine liposomes.

2. According to the preparation method of claim 1, the molar ratio of DSPC, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-COOH is 2:(0.5-1.5):(0.07-0.15):(0.015-0.028), preferably 2:1:0.11:0.

021.

3. The preparation method according to claim 1, wherein the methyl lotusine solution is a solution obtained by dissolving methyl lotusine in an organic solvent; preferably, the organic solvent is selected from methanol, ethanol, and DMSO.

4. The preparation method according to claim 1, wherein the solvent in the membrane solution is an organic solvent; preferably, the organic solvent is selected from: methanol, ethanol, and DMSO.

5. The preparation method according to claim 1, wherein the method for removing the organic solvent from the mixed solution to obtain the lipid film is: to perform rotary vacuum distillation of the mixed solution in a constant temperature water bath for a certain period of time; preferably, the temperature of the constant temperature water bath is 50-70℃; preferably, the temperature of the constant temperature water bath is 60℃.

6. A methylnephrine liposome prepared by the method according to any one of claims 1-5, which is configured to improve the skin absorption efficiency of methylnephrine.

7. The methylnephrine liposomes according to claim 6, wherein the particle size is 3-40 nm; preferably, the particle size is 5-25 nm; more preferably, the particle size is 5-20 nm; and more preferably, the particle size is about 8-15 nm.

8. A skin care product or pharmaceutical composition for preventing and / or treating photoaging damage of the skin, comprising methyl lotusine liposomes prepared by any of the preparation methods according to claims 1-5, or methyl lotusine liposomes according to any of claims 6-7.

9. The skin care product or pharmaceutical composition according to claim 8, wherein the form is cream, gel, dressing, spray, ointment, patch, mask, lotion or liquid.

10. The use of a methylnephrine liposome in the preparation of skin care products or pharmaceuticals for the prevention and / or treatment of photoaging damage to the skin.

Images